20:39 , May 2, 2019 |  BC Innovations  |  Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
17:57 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola...
19:14 , May 18, 2018 |  BC Extra  |  Company News

NIAID testing Regeneron mAbs to treat MERS

NIH’s National Institute of Allergy and Infectious Diseases began a Phase I trial in healthy volunteers to evaluate two mAbs from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat Middle East respiratory syndrome (MERS) coronavirus infection. The...
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Coronavirus S protein

Infectious disease INDICATION: Coronavirus Animal studies suggest sequential immunization with DNA vaccine and a subunit of coronavirus S protein could help prevent Middle East respiratory syndrome coronavirus (MERS-CoV) infection. In mice, two intramuscular injections of...